Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vilanterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 14/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | MC3R | P41968 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vilanterol SCHEMBL29623445 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL928189 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL29352123 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL17031687 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL142630 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL15614685 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Acetic Acid SCHEMBL925230 | 0.95 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL925229 | 0.95 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| Vilanterol SCHEMBL29448201 | 0.95 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL19236014 | 0.94 | ADRB2 (0.88) | ADRB2ADRB1SLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452924-B1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | HOVIONE SCIENTIA LTD (IE) | 2025-12-03 | — | — | EP | claimed |
| US-20250051261-A1 | Process to Prepare Vilanterol Trifenatate | HOVIONE SCIENTIA LIMITED (IE) | 2025-02-13 | — | — | US | claimed |
| EP-3335707-B1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LTD (GB) | 2024-04-17 | — | — | EP | claimed |
| WO-2023118833-A1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | HOVIONE SCIENTIA LIMITED (IE) | 2023-06-29 | — | — | WO | claimed |
| CN-116283512-A | Method for synthesizing vilanabro and salts thereof | 博诺康源(北京)药业科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-2611423-B2 | DRY POWDER INHALATION DRUG PRODUCTS EXHIBITING MOISTURE CONTROL PROPERTIES AND METHODS OF ADMINISTERING THE SAME | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-09-21 | — | — | EP | claimed |
| US-11116721-B2 | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol | GLAXO GROUP LIMITED (GB) | 2021-09-14 | — | — | US | claimed |
| EP-2400950-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | GLAXO GROUP LTD (GB) | 2019-05-22 | — | — | EP | claimed |
| EP-2506844-B1 | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | GLAXO GROUP LTD (GB) | 2017-12-20 | — | — | EP | claimed |
| EP-4452924-B1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | HOVIONE SCIENTIA LTD (IE) | 2025-12-03 | — | — | EP | disclosed |
| EP-4578502-A3 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | Glaxo Group Limited (GB) | 2025-10-08 | — | — | EP | disclosed |
| US-20250213803-A1 | DRY POWDER FORMULATIONS, DOSE CONTAINERS AND INHALERS CONTAINING THE SAME, AND METHODS | JPMORGAN CHASE BANK, N.A. | 2025-07-03 | — | — | US | disclosed |
| EP-4578502-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING 4-{(1 R)-2-[(6-{2-[(2,6-DICHLOROBENZYL)OXY]ETHOXY}HEXYL)AMINO]-1-HYDROXYETHYL}-2-(HYDROXYMETHYL)PHENOL | Glaxo Group Limited (GB) | 2025-07-02 | — | — | EP | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-20070221535-A1 | PACKAGE FOR MULTIPLE DOSE INHALATORS HAVING OPTIMISED EMPTYING PROPERTIES | WACHTEL HERBERT | 2007-09-27 | — | — | US | disclosed |
| WO-2007062726-A2 | DISPENSING DEVICE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007062745-A2 | INHALER AND STORE FOR A DRY MEDICAMENT FORMULATION AND RELATED METHODS AND USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007057362-A1 | NEEDLE FOR PUNCTURING POWDER CAPSULES FOR INHALATION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007045670-A1 | OPTICAL SEMI-QUANTITATIVE 100 % FILLING CHECK OF PHARMACEUTICAL CAPSULES ON CAPSULE FILLING MACHINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2005041922-A2 | COMPOSITION | GLAXO GROUP LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051261-A1 | Process to Prepare Vilanterol Trifenatate | AVPR2, CYP2D6, AVPR1B | ADRB2 145/4885ADRB1 144/4885SLC6A2 1129/4885 |
| US-11116721-B2 | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol | ADRB2, ADRA2B, ADRA2C | ADRB2 1/4885ADRB1 5/4885SLC6A2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.